PMID- 34204966
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210710
IS  - 2076-3921 (Print)
IS  - 2076-3921 (Electronic)
IS  - 2076-3921 (Linking)
VI  - 10
IP  - 6
DP  - 2021 Jun 3
TI  - Protective Effects of Oroxylin A on Retinal Ganglion Cells in Experimental Model 
      of Anterior Ischemic Optic Neuropathy.
LID - 10.3390/antiox10060902 [doi]
LID - 902
AB  - Nonarteritic anterior ischemic optic neuropathy (NAION) is the most common cause 
      of acute vision loss in older people, and there is no effective therapy. The 
      effect of the systemic or local application of steroids for NAION patients 
      remains controversial. Oroxylin A (OA) (5,7-dihydroxy-6-methoxyflavone) is a 
      bioactive flavonoid extracted from Scutellariae baicalensis Georgi. with various 
      beneficial effects, including anti-inflammatory and neuroprotective effects. A 
      previous study showed that OA promotes retinal ganglion cell (RGC) survival after 
      optic nerve (ON) crush injury. The purpose of this research was to further 
      explore the potential actions of OA in ischemic injury in an experimental 
      anterior ischemic optic neuropathy (rAION) rat model induced by photothrombosis. 
      Our results show that OA efficiently attenuated ischemic injury in rats by 
      reducing optic disc edema, the apoptotic death of retinal ganglion cells, and the 
      infiltration of inflammatory cells. Moreover, OA significantly ameliorated the 
      pathologic changes of demyelination, modulated microglial polarization, and 
      preserved visual function after rAION induction. OA activated nuclear factor E2 
      related factor (Nrf2) signaling and its downstream antioxidant enzymes 
      NAD(P)H:quinone oxidoreductase (NQO-1) and heme oxygenase 1 (HO-1) in the retina. 
      We demonstrated that OA activates Nrf2 signaling, protecting retinal ganglion 
      cells from ischemic injury, in the rAION model and could potentially be used as a 
      therapeutic approach in ischemic optic neuropathy.
FAU - Chien, Jia-Ying
AU  - Chien JY
AUID- ORCID: 0000-0002-3438-9435
AD  - Institute of Medical Sciences, Tzu Chi University, Hualien 970, Taiwan.
FAU - Lin, Shu-Fang
AU  - Lin SF
AD  - Institute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei 
      112, Taiwan.
FAU - Chou, Yu-Yau
AU  - Chou YY
AUID- ORCID: 0000-0001-9030-2173
AD  - Department of Molecular Biology and Human Genetics, Tzu Chi University, Hualien 
      970, Taiwan.
FAU - Huang, Chi-Ying F
AU  - Huang CF
AUID- ORCID: 0000-0003-4898-4937
AD  - Institute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei 
      112, Taiwan.
AD  - Institute of Biopharmaceutical Sciences, National Yang Ming Chiao Tung 
      University, Taipei 112, Taiwan.
FAU - Huang, Shun-Ping
AU  - Huang SP
AD  - Institute of Medical Sciences, Tzu Chi University, Hualien 970, Taiwan.
AD  - Department of Molecular Biology and Human Genetics, Tzu Chi University, Hualien 
      970, Taiwan.
AD  - Department of Ophthalmology, Taichung Tzu Chi Hospital, Taichung 472, Taiwan.
LA  - eng
GR  - 105-2628-B-320-002-MY3/Ministry of Science and Technology of TAIWAN/
PT  - Journal Article
DEP - 20210603
PL  - Switzerland
TA  - Antioxidants (Basel)
JT  - Antioxidants (Basel, Switzerland)
JID - 101668981
PMC - PMC8226497
OTO - NOTNLM
OT  - Nrf2
OT  - Oroxylin A
OT  - ischemic optic neuropathy
OT  - microglia
OT  - optical coherence tomography (OCT)
OT  - oxidative stress
OT  - retinal ganglion cell
OT  - visual evoked potential (VEP)
COIS- The authors declare no conflict of interest. The funders had no role in the 
      design of the study; in the collection, analyses, or interpretation of data; in 
      the writing of the manuscript; or in the decision to publish the results.
EDAT- 2021/07/03 06:00
MHDA- 2021/07/03 06:01
PMCR- 2021/06/03
CRDT- 2021/07/02 01:22
PHST- 2021/05/11 00:00 [received]
PHST- 2021/05/28 00:00 [revised]
PHST- 2021/05/31 00:00 [accepted]
PHST- 2021/07/02 01:22 [entrez]
PHST- 2021/07/03 06:00 [pubmed]
PHST- 2021/07/03 06:01 [medline]
PHST- 2021/06/03 00:00 [pmc-release]
AID - antiox10060902 [pii]
AID - antioxidants-10-00902 [pii]
AID - 10.3390/antiox10060902 [doi]
PST - epublish
SO  - Antioxidants (Basel). 2021 Jun 3;10(6):902. doi: 10.3390/antiox10060902.